As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decision to list in the US would complement the Company’s primary listing on the AIM market of the London Stock Exchange and Sensyne remains committed to being a UK-headquartered company. Any acquisition or strategic equity partnership would be consistent with Sensyne’s commitment to the ethical application of AI to patient data and its established strategic research agreements with the NHS and US health systems.
Lord (Paul) Drayson PhD FREng, Founder & CEO, commented:
“Now is the time for Sensyne to build on the success of its unique business model that has already created one of the world’s fastest growing patient data resources for life-sciences research. Our model provides a clear competitive advantage in terms of our commitment to patient data privacy, our close and collaborative research with our partners and our fair and transparent financial arrangements where we share the wealth that we create with the health systems that work with us. Our double bottom line approach to business will ensure that Sensyne becomes the leading company in its field and today’s announcement signals our clear commitment to that goal.”
The Company’s strategy remains centred on the ethical use of real-world patient data to support advances in medical and life science research for the benefit of patients. Sensyne has recently signed two strategic research agreements ("SRAs") with leading US health systems, St. Luke’s University Health Network in Pennsylvania and the Colorado Center for Personalized Medicine. Both SRAs build on the rapidly growing datasets accessed through ten SRAs signed to date with NHS Trusts, accelerating Sensyne’s strategy to be a global leader in clinical AI with one of the largest sets of de-identified and anonymised real-world patient data, including longitudinal phenotypic and genomic data needed for life sciences research and development.
Sensyne now has access to a total of approximately 18.2 million unique patient records (approximately 8.4 million in the UK and approximately 9.8 million in the US) representing more than a 600% increase in size since September 2020. The Company aims to build an ethically sourced real-world dataset of approximately 100 million patient records by the end of 2024.
Sensyne pursues a “double bottom line” business model that includes working in partnership with healthcare providers such as the NHS and US health systems to provide a financial return to partner healthcare systems through equity ownership in the Company and a share of revenues generated by the Company as it delivers public health benefits and accelerates the discovery and development of new medicines.